Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE:TMO) announced over $600 million in investments to expand its bioprocessing production capabilities through 2022. This expansion aims to more than double manufacturing capacity to support biopharma customers during COVID-19 and future vaccine developments. The investment will create over 1,500 jobs across 11 sites in the Americas, Europe, and Asia. Key areas of expansion include single-use technologies, purification resins, and cell culture media production, enhancing supply chain resilience and customer support.
Thermo Fisher Scientific (NYSE: TMO) has finalized its acquisition of Mesa Biotech, enhancing its point-of-care molecular diagnostics capabilities. The Accula System, developed by Mesa, allows rapid, accurate testing for COVID-19 and other diseases, providing results in just 30 minutes. This strategic move is expected to generate approximately $200 million in revenue for Thermo Fisher in 2021. The acquisition aims to leverage Thermo Fisher's resources with Mesa's innovative technology, positioning the company to meet the growing demand for point-of-care diagnostics globally.
Thermo Fisher Scientific (NYSE: TMO) will be represented by CEO Marc N. Casper at the 41st Annual Cowen Healthcare Conference on March 3, 2021, at 10:20 a.m. EDT. The event will be held virtually, and interested parties can access the presentation through the company's website. With annual revenues exceeding $30 billion, Thermo Fisher Scientific is a leading provider of scientific services and products, aiming to make the world healthier, cleaner, and safer.
Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.26 per common share, reflecting an 18% increase from the prior $0.22 payment. The dividend is payable on April 16, 2021, to shareholders of record by March 16, 2021. With annual revenues exceeding $30 billion, Thermo Fisher continues to lead in serving scientific needs globally, supporting research and improving diagnostics through its renowned brands.
Thermo Fisher Scientific (NYSE:TMO) has acquired cell sorting technology assets from Propel Labs, enhancing its Biosciences business. This includes the Bigfoot Spectral Cell Sorter, which offers advanced sorting capabilities and faster throughput. Approximately 40 employees from Propel Labs will join Thermo Fisher, while Propel will continue operating independently. The Bigfoot technology aims to meet growing demands in cell and gene therapies, addressing significant challenges in cytometry analysis. Thermo Fisher's annual revenue exceeds $30 billion, positioning it well to improve healthcare outcomes.
Summary not available.
Thermo Fisher Scientific (NYSE: TMO) reported impressive financial results for Q4 and full year 2020, showing a 54% increase in Q4 revenue to $10.55 billion and a 26% rise in annual revenue to $32.22 billion. Q4 GAAP diluted EPS surged 151% to $6.24, while adjusted EPS increased 100% to $7.09. Strong growth driven by $3.2 billion in COVID-19 response revenue, alongside significant investments in innovation and infrastructure, supports a robust long-term growth strategy. The company also returned $1.8 billion in capital to shareholders through buybacks and dividends.
Thermo Fisher Scientific (NYSE: TMO) announced its acquisition of Mesa Biotech, a molecular diagnostic company, for approximately $450 million in cash, with the potential for an additional $100 million based on performance milestones. Mesa Biotech specializes in rapid PCR-based testing for infectious diseases, including COVID-19 and influenza, with revenues of about $45 million in 2020. The deal, aimed at enhancing Thermo Fisher's diagnostics portfolio, is expected to close in Q1 2021, pending regulatory approvals.
Thermo Fisher Scientific (TMO) announced the acquisition of Henogen S.A., Novasep's viral vector manufacturing business, for approximately €725 million. This strategic move aims to enhance Thermo Fisher's capabilities in cell and gene therapies, adding significant manufacturing capacity in Belgium. The Henogen business, recognized for its expertise and operational excellence, generated an estimated €80 million in revenue in 2020. The acquisition aligns with Thermo Fisher's mission to support global biotech clients and strengthens its position in the European market.
Thermo Fisher Scientific (NYSE: TMO) announced that CEO Marc N. Casper will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 p.m. (EDT). The presentation will cover the company's insights on the COVID-19 pandemic and future financial outlook. The webcast can be accessed through the Investors section of the company's website. Thermo Fisher has an annual revenue exceeding $25 billion and employs over 75,000 people globally.